glp 1 agonists reduce inflammation Central glucagon-like peptide receptor activation inhibits Toll-like receptor agonist-induced inflammation: Cell Metabolism Frontiers | GLP-1 Receptor Agonists:

Similarly, in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model, GLP-1 analogues were reported to protect the brain from MPTP-induced pathological effects, such as movement disorders, increased levels of -synuclein, chronic inflammation in the brain, loss of dopaminergic neurons, oxidative stress, and expression of growth factors (65)

This binding can activate the cells against degeneration due to mitochondrial dysfunction that leads to a reduction of dopamine transmission, the deposition of a-synuclein, and the presence of oxidative stress ( Figure 2 )

K., Jalewa, J

Through these studies, potential new opportunities have risen to utilize GLP-1 receptor agonists to treat nonalcoholic fatty liver disease (NAFLD), Parkinson disease, Alzheimer disease, osteoarthritis, and chemical dependency

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy focus on alogliptin

doi: 10.2337/DC12-2462